The U.S. Food and Drug Governance is streamlining the path for innovative cell and gene therapies, announcing a more flexible approach to overseeing manufacturing standards. This shift, revealed January 11, 2026, aims to expedite product development while maintaining rigorous quality control for these possibly life-changing treatments.

Easing the Bottleneck for Breakthrough Therapies

What’s the FDA doing to speed up access to cell and gene therapies? The agency is adapting its chemistry, manufacturing, and control (CMC) requirements to better suit the unique characteristics of these complex, frequently enough individualized treatments. This means a more tailored regulatory process, designed to encourage innovation without compromising patient safety.

“Regulatory flexibility must be tailored for cell and gene therapies,” said FDA Commissioner Marty Makary, M.D., M.P.H. “These are common-sense reforms that will address the unique characteristics of cell and gene therapies and foster more innovation.”

Over the past decade, the FDA’s Center for Biologics Evaluation and Research (CBER) has approved nearly 50 cell and gene therapies, sparking excitement within the medical community and offering hope to patients with previously untreatable conditions.

  • The FDA is adapting its manufacturing standards for cell and gene therapies.
  • This change aims to expedite the development of these innovative treatments.
  • The agency emphasizes that safety and quality will not be compromised.
  • The FDA hosted a roundtable discussion in June to advance the field.

“CBER is proactively communicating about regulatory flexibilities that were previously applied case-by-case to select CGT therapies,” stated Vijay Kumar M.D., Acting Director, Office of therapeutic Products at CBER. “By communicating these approaches broadly, we aim to expedite product development across the CGT field. It is vital that every sponsor, no matter the CBER reviewer team they engage with, understand what types of regulatory flexibility may be scientifically acceptable.”

The FDA acknowledges the rapid pace of scientific advancement and is committed to removing perceived barriers to progress. These flexibilities are intended to enable faster development timelines while upholding the agency’s commitment to ensuring the safety, purity, and potency of these groundbreaking therapies.

in June, the FDA convened a Cell and Gene Therapy Roundtable, bringing together experts to discuss the future of this rapidly evolving field.

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.